# Cannabinol Use in Patients With Insomnia Disorder

> **NCT05344170** · PHASE1,PHASE2 · COMPLETED · sponsor: **Woolcock Institute of Medical Research** · enrollment: 20 (actual)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** 30 mg Cannabinol (CBN)
- **DRUG:** 300 mg Cannabinol (CBN)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05344170
- **Lead sponsor:** Woolcock Institute of Medical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-24
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-09-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05344170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05344170, "Cannabinol Use in Patients With Insomnia Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05344170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*